Study outcomes
Visual impairment, visual impairment, blindness
BLINDNESS, ADVERSE EVENTS, SECONDARY, COMPLICATIONS, VISUAL IMPAIRMENT
The primary clinical outcomes were the changes in BCVA from baseline to the end of IVI treatment and the 12-month visit, as well as the number of IVIs. The secondary outcome measures were the percentages of patients with improved, stable and decreased BCVA; the prevalence of visual impairment and blindness at 12 months; and the occurrence of CMVR-related complications and other adverse events. Visual impairment and blindness were defined as visual acuity worse than 20/40 and worse than or equal to 20/200, respectively. Therapeutic efficacy was divided into three levels: (1) improved: vision improved by ≥ 2 lines on the acuity chart; (2) stable: vision fluctuated by less than 2 lines; and (3) decreased: vision worsened by ≥ 2 lines on the acuity chart or progressed to NLP.